KR102317884B1 - 항체의 시험관 내 당조작 - Google Patents

항체의 시험관 내 당조작 Download PDF

Info

Publication number
KR102317884B1
KR102317884B1 KR1020197017701A KR20197017701A KR102317884B1 KR 102317884 B1 KR102317884 B1 KR 102317884B1 KR 1020197017701 A KR1020197017701 A KR 1020197017701A KR 20197017701 A KR20197017701 A KR 20197017701A KR 102317884 B1 KR102317884 B1 KR 102317884B1
Authority
KR
South Korea
Prior art keywords
antibody
val
ser
pro
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197017701A
Other languages
English (en)
Korean (ko)
Other versions
KR20190082942A (ko
Inventor
로베르토 팔켄슈타인
하이코 발흐
세바슈티안 말릭
마르코 토만
폰 로만 마티아스 프라이허
잉그리트 그루너트
롤란트 도른
미하엘 힝가르
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60997429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102317884(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20190082942A publication Critical patent/KR20190082942A/ko
Application granted granted Critical
Publication of KR102317884B1 publication Critical patent/KR102317884B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020197017701A 2016-12-21 2017-12-19 항체의 시험관 내 당조작 Active KR102317884B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16205587.5 2016-12-21
EP16205587 2016-12-21
EP17157002 2017-02-20
EP17157002.1 2017-02-20
PCT/EP2017/083429 WO2018114877A1 (en) 2016-12-21 2017-12-19 In vitro glycoengineering of antibodies

Publications (2)

Publication Number Publication Date
KR20190082942A KR20190082942A (ko) 2019-07-10
KR102317884B1 true KR102317884B1 (ko) 2021-10-26

Family

ID=60997429

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197017701A Active KR102317884B1 (ko) 2016-12-21 2017-12-19 항체의 시험관 내 당조작

Country Status (11)

Country Link
US (2) US20200165320A1 (https=)
EP (1) EP3559248B2 (https=)
JP (1) JP6850351B2 (https=)
KR (1) KR102317884B1 (https=)
CN (2) CN110088291A (https=)
AU (1) AU2017384276B9 (https=)
CA (1) CA3044920C (https=)
IL (1) IL267351A (https=)
MX (1) MX2019006266A (https=)
TW (1) TWI780097B (https=)
WO (1) WO2018114877A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117887794A (zh) * 2016-12-21 2024-04-16 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작
US20200017600A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
US20230272105A1 (en) 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
IL311141A (en) 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
WO2025049881A1 (en) * 2023-09-01 2025-03-06 Catalent Pharma Solutions, Llc Dnase co-expression in host cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500002A (ja) 2009-07-30 2013-01-07 エフ．ホフマン−ラ ロシュ アーゲー 酵素による抗体処理方法
WO2015123754A1 (en) * 2014-02-18 2015-08-27 The University Of Manitoba Methods to produce single glycoform antibodies
WO2016037947A1 (en) * 2014-09-10 2016-03-17 F. Hoffmann-La Roche Ag Galactoengineered immunoglobulin 1 antibodies

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP0576592B1 (en) 1991-03-18 2000-05-31 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP1460425A1 (en) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
EP1740615B1 (en) 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005111627A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060127950A1 (en) 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
TW200812616A (en) 2006-05-09 2008-03-16 Genentech Inc Binding polypeptides with optimized scaffolds
US20070266448A1 (en) 2006-05-11 2007-11-15 Alexander Lifke Method for the production of antibodies
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AU2008291358A1 (en) * 2007-08-31 2009-03-05 F. Hoffmann-La Roche Ag Glycosylation profile analysis
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2012037407A1 (en) 2010-09-17 2012-03-22 Prozyme, Inc. Isolation and deglycosylation of glycoproteins
PT2768857T (pt) * 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
IN2014DN06806A (https=) * 2012-02-10 2015-05-22 Univ Maryland
KR102317884B1 (ko) 2016-12-21 2021-10-26 에프. 호프만-라 로슈 아게 항체의 시험관 내 당조작

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013500002A (ja) 2009-07-30 2013-01-07 エフ．ホフマン−ラ ロシュ アーゲー 酵素による抗体処理方法
WO2015123754A1 (en) * 2014-02-18 2015-08-27 The University Of Manitoba Methods to produce single glycoform antibodies
WO2016037947A1 (en) * 2014-09-10 2016-03-17 F. Hoffmann-La Roche Ag Galactoengineered immunoglobulin 1 antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Current Topics in Microbiology and Immunology, Vol. 382, pp. 165-199 (2014.)
European Journal of Phamaceutics and Biopharmaceutics, Vol. 100, pp. 94-100 (2016.01.13.)
PNAS, Vol. 112, pp. 10611-10616 (2015.)

Also Published As

Publication number Publication date
CA3044920A1 (en) 2018-06-28
EP3559248A1 (en) 2019-10-30
JP6850351B2 (ja) 2021-03-31
MX2019006266A (es) 2019-08-21
AU2017384276B2 (en) 2020-07-02
BR112019010485A2 (pt) 2019-09-10
TWI780097B (zh) 2022-10-11
TW201835333A (zh) 2018-10-01
JP2020501577A (ja) 2020-01-23
IL267351A (en) 2019-08-29
CN110088291A (zh) 2019-08-02
KR20190082942A (ko) 2019-07-10
US20240101643A1 (en) 2024-03-28
EP3559248B1 (en) 2021-11-17
CA3044920C (en) 2022-06-28
WO2018114877A1 (en) 2018-06-28
US20200165320A1 (en) 2020-05-28
AU2017384276B9 (en) 2020-11-26
EP3559248B2 (en) 2024-11-20
CN119685431A (zh) 2025-03-25
AU2017384276A1 (en) 2019-05-30

Similar Documents

Publication Publication Date Title
KR102317884B1 (ko) 항체의 시험관 내 당조작
KR102390246B1 (ko) 항체의 시험관내 글리코조작에 있어서의 효소의 재사용
KR102293106B1 (ko) 항체의 시험관 내 당조작 방법
HK40123043A (zh) 用於体外糖工程化抗体的方法
HK40106545A (zh) 用於体外糖工程化抗体的方法
HK40011892B (zh) 用於体外糖工程化抗体的酶的再使用

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20190619

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
AMND Amendment
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201123

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210525

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201123

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210525

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210120

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20190701

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210823

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210723

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210525

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210120

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190701

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211020

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211020

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee